2015
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllograftsAutograftsBiopsy, NeedleFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHematopoietic Stem Cell TransplantationHumansImmunohistochemistryLymphoma, T-CellLymphoma, T-Cell, CutaneousMaleMiddle AgedPanniculitisPositron-Emission TomographyRetrospective StudiesRisk AssessmentSampling StudiesSkin NeoplasmsTreatment OutcomeConceptsHematopoietic stem cell transplantationT-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAllogeneic hematopoietic stem cell transplantationPanniculitis-like T-cell lymphomaCutaneous T-cell lymphomaStem cell transplantationPCGD-TCLCell transplantationPrimary cutaneous γδ T-cell lymphomaCutaneous γδ T-cell lymphomaAutologous hematopoietic stem cell transplantationOutcome of HSCTAdvanced-stage mycosis fungoidesΓδ T-cell lymphomaPanniculitic T-cell lymphomaAggressive T-cell lymphomaMatched-related donorsMatched-unrelated donorsT-cell infiltratesPromising treatment modalityAggressive therapyMost patientsMycosis fungoidesInferior outcomes
2013
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides
Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAge FactorsAgedAnalysis of VarianceCohort StudiesDermatomycosesDose Fractionation, RadiationDose-Response Relationship, RadiationElectronsFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPrognosisRadiodermatitisRadiotherapy DosageRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex FactorsSkin Diseases, BacterialSkin NeoplasmsWhole-Body IrradiationConceptsTotal skin electron beam therapyMycosis fungoidesSkin infectionsElectron beam therapyAcute toxicityBeam therapyAcute treatment toxicityRetrospective study designIncidence of infectionRisk of infectionCommon toxicitiesTreatment toxicityCutaneous infectionsSkin painBaseline incidenceToxicity gradeGrade 3Modern seriesGrade 2Grade 1Consecutive coursesFungoidesInfectionStudy designGrade 4
2002
Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®)
Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®). Clinical Lymphoma Myeloma & Leukemia 2002, 2: 222-228. PMID: 11970761, DOI: 10.3816/clm.2002.n.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsDiphtheria ToxinDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousInterleukin-2Lymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm StagingPatient SatisfactionProbabilityPrognosisProspective StudiesQuality of LifeRecombinant Fusion ProteinsReference ValuesRisk AssessmentSkin NeoplasmsStatistics, NonparametricTreatment OutcomeConceptsCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaDenileukin diftitoxPruritus severityOverall QoLSkin appearanceCutaneous T-cell lymphoma patientsAdverse transfusion-related eventsCancer Therapy-General (FACT-G) questionnaireT-cell lymphoma patientsPhase III trialsVascular leak syndromeT-cell lymphomaTransfusion-related eventsSignificant myelosuppressionIII trialsSkin severityStudy endpointLymphoma patientsOutpatient basisIndividual subscale scoresFunctional assessmentPatientsDiftitoxTreatment cycles